Related Experiment Video
Updated: Aug 14, 2026
Performing Behavioral Tasks in Subjects with Intracranial Electrodes
Published on: October 2, 2014
Technology evaluation: ING-1, XOMA
1Section of Clinical Pharmacology, Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH 03756, USA. Lionel.D.Lewis@Dartmouth.edu
XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, as a potential treatment for carcinoma and solid tumors. In November 2000, ING-1 entered phase I trials in the US and by February 2002, phase I/II trials had been initiated.
XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, as a potential treatment for carcinoma and solid tumors. In November 2000, ING-1 entered phase I trials in the US and by February 2002, phase I/II trials had been initiated.
